Aripiprazole and <i>CYP2D6</i> : A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities
This study suggests that the incidence of metabolic abnormalities beyond LDL may not be higher in CYP2D6 poor metabolizers compared to normal metabolizers. Further research is needed to investigate clinically meaningful outcomes in relation to CYP2D6 and aripiprazole.
Authors
- Brian Meissner
- F. Younes
- Natasha Petry (ORCID: https://orcid.org/0000-0001-5089-9286)
- Amanda Massmann (ORCID: https://orcid.org/0000-0002-5401-5318)
- Max Weaver (ORCID: https://orcid.org/0009-0009-1351-9972)
Institutions
- Sanford Health (US)
- University of South Dakota (US)
- Sanford Medical Center (US)
- Sanford Medical Center (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1093/ajhp/zxaf345
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00